doctors
nurses
new patient coordinator
Guido Tricot, MD, PhD, is the director of the Utah Blood and Marrow Transplant and Myeloma Program. He has been researching and treating multiple myeloma for over twenty years. Tricot is also a professor in the Department of Medicine at the University of Utah School of Medicine.
His team's treatment strategies are based on tandem autologous transplantation, a treatment approach that has increased the median survival rate of patients to ten years or more, compared to 2.5 to 3 years with conventional chemotherapy. The long-term outcome data of Dr. Tricot's work have been published extensively.
He has received several research grants from the National Cancer Institute and has been principal investigator on many clinical trials.
Dr. Tricot regularly gives presentations on multiple myeloma all over the United States and the world. His research has appeared in numerous publications, including New England Journal of Medicine, the Lancet, the Journal of Clinical Oncology, Blood, Cancer Research, Clinical Cancer Research, the British Journal of Haematology, Seminars in Hematology, and Hematology/Oncology Clinics of North America.
He received his medical and doctoral degree at the University of Leuven in Belgium. Before joining Huntsman Cancer Institute, he was Director of Clinical Research at the University of Arkansas Myeloma Institute for Research and Therapy, the largest myeloma program in the world.
Dr. Tricot has also served as Director of Bone Marrow and Stem Cell Transplantation at the Greenebaum Cancer Center at the University of Maryland and at Indiana University.
Maurizio Zangari, MD, is the director of experimental therapeutics for the Utah Blood and Marrow Transplant and Myeloma Program and professor in the Department of Medicine at the University of Utah School of Medicine. He has been researching novel anticancer agents, bone formation, and the treatment difficulties associated with hypercoagulability in cancer patients for over two decades.
He has been principal investigator on numerous clinical trials funded by the National Cancer Institutes and privately-held pharmaceutical companies. The long-term results of Dr. Zangari’s heavily-researched coagulation, transplant, and relapse therapy studies have been published in many scientific journals such as Thrombosis Research, Blood, Bone Marrow Transplantation, the British Journal of Haematology, the Journal of Clinical Oncology, Leukemia and Lymphoma, the American Journal of Medicine, Seminars in Hematology, Experimental Hematology, Clinical Cancer Research, Blood Coagulation and Fibrinolysis, Clinical Advances in Hematology and Oncology, Current Pharmaceutical Biotechnology, Expert Opinion on Investigational Drugs, and the New England Journal of Medicine.
He received his medical degree from the University of Padua in Italy. Subsequently, he received additional training in ENT and Oncology from Ospedale Civele de Camposampiero, and in emergency medicine at the Caserma Ederle U.S. Army Hospital in Vicenza, Italy.
Before coming to Huntsman Cancer Institute, Dr. Zangari performed fellowships in Hematology and Bone Marrow Transplantation at Mount Sinai Hospital in New York and was appointed Instructor in Medicine. He later joined the Myeloma Institute for Research and Therapy, the largest myeloma program in the world, as an Associate Professor of Medicine.
